Spyre Therapeutics (SYRE) said late Monday it priced an underwritten public offering of about 7.3 million shares of its common stock at $27.50 per share for expected gross proceeds of $200 million.
The company also granted the underwriters a 30-day option to buy up to an additional about 1.1 million shares. The offering is expected to close on or about Wednesday.
Price: 28.41, Change: -0.26, Percent Change: -0.91